chikungunya
diseas
result
infect
arboviru
chikungunya
viru
chikv
symptom
chikv
includ
fever
persist
sever
arthriti
recent
year
sever
antivir
drug
evalu
clinic
trial
howev
regist
antivir
approv
clinic
therapi
studi
establish
highthroughput
screen
ht
system
base
chikv
mediat
insect
cell
fusion
inhibit
assay
screen
system
abl
search
potenti
antichikv
drug
vitro
use
system
four
compound
niclosamid
nitazoxanid
niflum
acid
tolfenam
acid
identifi
compound
analyz
use
microneutr
assay
determin
niclosamid
nitazoxanid
exhibit
abil
chikvinduc
cpe
antichikv
abil
compound
confirm
rtqpcr
ifa
moreov
niclosamid
nitazoxanid
found
limit
viru
entri
inhibit
viral
releas
celltocel
transmiss
possess
broad
antialphaviu
activ
includ
two
clinic
chikv
isol
two
alphavirus
sindbi
viru
sinv
semliki
forest
viru
sfv
conclus
find
suggest
niclosamid
nitazoxanid
abl
inhibit
chikv
entri
transmiss
might
provid
basi
develop
novel
human
drug
therapi
chikv
alphaviru
infect
chikungunya
diseas
caus
infect
chikungunya
viru
chikv
sporad
outbreak
occur
africa
asia
decad
outbreak
chikungunya
diseas
la
r
eunion
island
franc
result
onethird
resid
becom
infect
outbreak
viru
also
transmit
south
india
parola
et
al
southern
europ
includ
itali
franc
gould
et
al
rezza
et
al
furthermor
carribean
affect
outbreak
chikungunya
diseas
sinc
decemb
viru
becom
public
health
threat
central
america
weaver
forrest
togeth
two
aforement
outbreak
led
hundr
death
caus
one
million
peopl
fall
ill
mavalankar
et
al
weaver
forrest
symptom
chikungunya
diseas
includ
high
fever
arthriti
arthralgia
headach
nausea
vomit
conjunct
patient
also
suffer
sever
joint
pain
week
month
burt
et
al
weaver
lecuit
chikv
alphaviru
belong
famili
togavirida
classifi
risk
pathogen
stapl
et
al
enter
cell
receptormedi
endocytosi
ie
bind
phase
upon
entri
endosom
undergo
acidif
lead
conform
chang
chikv
envelop
glycoprotein
voss
et
al
envelop
glycoprotein
form
trimer
caus
viral
membran
endosom
membran
fuse
togeth
form
pore
ie
fusion
phase
van
duijlricht
et
al
viral
genom
releas
cytosol
chikv
rna
includ
genom
rna
subgenom
rna
genom
rna
encod
four
nonstructur
protein
respons
viral
genom
synthesi
ie
genom
synthesi
chikv
envelop
glycoprotein
capsid
protein
translat
subgenom
rna
endoplasm
reticulum
er
deliv
golgi
apparatu
process
glycosyl
structur
protein
form
spike
complex
transport
plasma
membran
final
spike
complex
assembl
nucleocapsid
core
schwartz
albert
van
duijlricht
et
al
virus
bud
releas
becom
matur
virion
ie
releas
phase
chikv
also
spread
celltocel
transmiss
allow
virion
effici
avoid
attack
host
immun
system
hahon
zimmerman
antivir
drug
develop
disrupt
life
cycl
viru
indic
four
main
step
viral
multipl
includ
bind
fusion
genom
synthesi
transmiss
includ
releas
celltocel
transmiss
abdelnabi
et
al
parashar
cherian
viru
fusion
critic
step
chikv
infect
fusion
process
depend
lowph
presenc
cholesterol
kuo
et
al
kuo
et
al
similar
find
report
sindbi
viru
sinv
semliki
forest
viru
sfv
bogg
et
al
chanelvo
kielian
kempf
et
al
lanzrein
et
al
therefor
fusion
inhibitor
potenti
candid
antichikv
drug
report
describ
use
chikv
mediat
insect
cell
fusion
inhibit
assay
use
baculovirusbas
express
highthroughput
screen
ht
system
search
novel
antichikv
drug
macarron
et
al
also
discuss
effect
mechan
two
potenti
antichikv
candid
niclosamid
nitazoxanid
result
suggest
antivir
properti
niclosamid
nitazoxanid
made
promis
compound
develop
antichikv
drug
atcc
babi
hamster
kidney
cell
cell
grown
dulbecco
modifi
eagl
medium
dmem
invitrogen
catalog
contain
fetal
bovin
serum
fb
invitrogen
catalog
c
co
cell
grown
ii
sfm
invitrogen
catalog
contain
fb
c
use
cell
propag
chikv
strain
african
prototyp
provid
center
diseas
control
roc
tcdc
mutant
provid
tcdc
well
sindbi
viru
origin
strain
semliki
forest
virus
origin
strain
swt
ie
baculoviru
construct
chikv
genom
vector
baculoviru
use
control
propag
cell
kuo
et
al
fdaapprov
drug
librari
selleckchem
catalog
mm
dmso
purchas
selleckchem
facilit
chikv
mediat
insect
cell
fusion
inhibit
assay
niclosamid
sigma
nitazoxanid
sigma
suramin
sigma
purchas
sigmaaldrich
toronto
research
chemic
trc
purchas
trc
cell
transduc
vacchikv
swt
kuo
et
al
moi
multipl
infect
held
c
overnight
vector
baculovirus
vacrhir
transduc
time
condit
delay
membran
fusion
second
day
replac
old
medium
fresh
medium
ph
third
day
infect
cell
pretreat
mm
fdaapprov
drug
ph
h
medium
replac
fresh
medium
ph
contain
mgml
cholesterol
mm
fdaapprov
drug
cell
incub
h
imag
viral
fusion
captur
use
invert
fluoresc
microscop
olympu
fusion
area
analyz
imag
j
softwar
fusion
index
calcul
use
formula
e
cell
count
total
area
fuse
cellsaverag
area
singl
cell
ho
et
al
relat
fusion
index
test
compound
normal
respect
group
swt
cell
infect
chikv
strain
moi
presenc
compound
indic
dosag
fig
fig
incub
period
day
infect
cell
fix
stain
use
crystal
violet
solut
infect
cell
fix
incub
rabbit
antichikv
antibodi
kuo
et
al
antidsrna
monoclon
antibodi
scicon
catalog
h
prestain
cell
subsequ
wash
three
time
pb
incub
alexa
fluor
goat
antirabbit
igg
invitrogen
alexa
fluor
goat
antimous
igg
invitrogen
alexa
fluor
goat
antimous
igg
invitrogen
h
final
wash
pb
imag
cell
captur
use
invert
fluoresc
microscop
olympu
total
rna
isol
use
trizol
reagent
invitrogen
catalog
quantitect
sybr
green
rtpcr
kit
qiagen
catalog
use
quantifi
viral
rna
actin
rna
primer
sequenc
list
tabl
fragkoudi
et
al
ho
et
al
sane
et
al
specif
rtqpcr
conduct
use
roch
lightcycl
system
min
c
min
c
fortyf
addit
cycl
cycl
consist
c
c
c
rel
valu
calcul
use
ddct
method
experi
perform
triplic
cell
viabil
examin
use
cell
count
assay
sigmaaldrich
catalog
cell
seed
plate
cell
incub
candid
drug
indic
dosag
h
reagent
dilut
cultur
medium
vv
replac
well
h
incub
optic
densiti
od
detect
use
tecan
infinit
pro
multipl
reader
cell
viabil
determin
accord
follow
formula
cell
viabil
od
treat
cell
e
od
refer
control
control
cell
e
refer
control
cell
infect
chikv
strain
moi
incub
indic
concentr
niclosamid
nitazoxanid
h
c
wash
dmem
infect
cell
cover
medium
contain
ml
agaros
incub
day
final
infect
cell
fix
stain
crystal
violet
solut
plaqu
format
count
normal
respect
viru
control
group
result
obtain
least
three
independ
experi
cell
infect
chikv
strain
moi
incub
h
virus
remov
medium
replac
addit
mm
niclosamid
mm
nitazoxanid
ad
cell
prior
infect
pre
infect
co
postinfect
post
stage
h
incub
period
intracellular
product
chikv
rna
cell
determin
rtqpcr
percentag
inhibit
associ
compound
normal
respect
viru
control
group
vc
releas
chikv
progeni
collect
supernat
analyz
use
tcid
assay
cell
seed
well
plate
infect
chikv
strain
moi
incub
period
h
inoculum
subsequ
remov
medium
replac
fresh
medium
contain
chikv
neutral
antibodi
ho
et
al
kuo
et
al
indic
drug
cell
incub
h
fix
stain
antidsrna
monoclon
antibodi
scicon
catalog
accord
standard
ifa
protocol
final
nuclei
stain
dapi
number
cell
per
focu
could
count
ho
et
al
use
dissect
microscop
hamlet
observ
morpholog
anomali
zebrafish
includ
chorion
attach
debri
delay
develop
lack
spontan
movement
pericardi
edema
yolk
sac
edema
bent
trunk
tail
malform
uninfl
swim
bladder
also
record
hatch
surviv
rate
express
number
hatch
dead
embryo
compar
control
group
store
h
post
fertil
hpf
embryo
plate
concentr
two
embryoswel
well
contain
ml
test
solut
ie
either
niclosamid
mm
nitazoxanid
mm
specif
embryo
store
c
day
h
lightdark
photoperiod
updat
daili
ho
et
al
studi
protocol
approv
institut
anim
care
use
committe
iacuc
nation
taiwan
univers
conform
criteria
outlin
guid
care
use
laboratori
anim
nation
institut
health
experi
complet
zebrafish
sacrif
use
tricain
sigmaaldrich
catalog
wherebi
effort
made
minim
suffer
experiment
result
analyz
use
student
ttest
kaplanmei
test
perform
graphpad
prism
softwar
data
obtain
least
three
independ
experi
p
valu
consid
signific
chikv
subgenom
rna
encod
structur
protein
includ
capsid
c
envelop
protein
play
role
receptor
bind
membran
fusion
coexpress
chikv
structur
protein
enhanc
green
fluoresc
protein
egfp
bicistron
baculoviru
express
system
util
acquir
egfpposit
cell
express
chikv
structur
protein
egfpposit
cell
abl
character
cell
fusion
chen
et
al
illustr
chikv
mediat
insect
cell
fusion
inhibit
assay
protocol
shown
fig
fusion
phenomenon
observ
cell
transduc
control
vector
baculoviru
vacrhir
whether
fig
fig
cell
transduc
swt
fusion
phenomenon
retard
fig
acceler
presenc
cholesterol
fig
therefor
group
swt
fig
fusion
control
compound
detect
condit
chikv
neutral
antibodi
kuo
et
al
fig
abl
inhibit
chikv
mediat
cell
fusion
igg
fig
find
suggest
fusion
phenomenon
specif
trigger
chikv
structur
protein
suramin
shown
possess
antichikv
activ
fusion
inhibit
thu
use
posit
control
ho
et
al
convers
consid
chikv
replic
antagonist
use
neg
control
suramin
abl
disrupt
cell
fusion
swt
transduct
fig
could
fig
find
provid
evid
suggest
novel
platform
use
identifi
potenti
fusion
inhibitor
use
chikv
mediat
insect
cell
fusion
inhibit
assay
perform
highthroughput
screen
chikv
fusion
inhibitor
obtain
fdaapprov
drug
librari
afterward
relat
fusion
index
normal
respect
group
swt
fig
determin
four
compound
niclosamid
nitazoxanid
niflum
acid
tolfenam
acid
fusion
index
lower
red
point
fig
zscore
antichikv
abil
character
microneutr
assay
niclosamid
nitazoxanid
exhibit
activ
chikvinduc
cpe
fig
compound
intermedi
inhibitori
activ
fusion
index
test
microneutr
assay
confirm
inhibit
chikv
infect
fig
result
indic
fusion
inhibitor
fusion
index
potenti
candid
develop
antichikv
drug
confirm
antichikv
effect
niclosamid
nitazoxanid
rtqpcr
ifa
perform
test
cell
infect
chikv
moi
presenc
variou
dosag
niclosamid
nitazoxanid
intracellular
rna
extract
h
pi
chikv
rna
level
normal
actin
percent
inhibit
chikv
rna
level
normal
respect
chikv
infect
group
defin
ec
effect
niclosamid
nitazoxanid
cell
viabil
analyz
assay
defin
cc
niclosamid
show
ec
valu
mm
cc
valu
mm
convers
ec
cc
valu
nitazoxanid
determin
mm
mm
fig
tabl
addit
cell
infect
chikv
moi
presenc
mm
niclosamid
mm
nitazoxanid
incub
h
antichikv
antibodi
use
ifa
determin
chikv
replic
niclosamid
nitazoxanid
confirm
possess
antichikv
activ
fig
toxic
compound
also
analyz
vivo
use
zebrafish
embryo
neither
compound
found
neg
affect
surviv
bodi
length
develop
hatch
rate
fig
find
indic
dosag
niclosamid
nitazoxanid
appli
safe
could
use
verifi
antichikv
effect
niclosamid
nitazoxanid
inhibit
chikv
mediat
cell
fusion
therefor
compound
might
also
abl
suppress
earli
stage
chikv
infect
investig
possibl
cell
infect
chikv
moi
cotreat
niclosamid
mm
nitazoxanid
mm
c
h
incub
period
inoculum
remov
treat
cell
wash
cover
agaros
without
drug
determin
effect
niclosamid
nitazoxanid
viru
entri
compound
found
significantli
inhibit
chikv
entri
dosedepend
manner
fig
investig
stage
chikv
infect
affect
niclosamid
nitazoxanid
timeofaddit
assay
use
cell
infect
chikv
moi
h
incub
subsequ
inoculum
remov
place
fresh
medium
mm
niclosamid
mm
nitazoxanid
ad
prior
infect
pre
infect
co
postinfect
post
h
pi
cell
lysat
supernat
collect
analyz
rtqpcr
tcid
assay
fig
fig
show
percent
inhibit
observ
intracellular
chikv
rna
level
specif
niclosamid
nitazoxanid
present
inhibit
chikv
attach
infect
stage
co
find
confirm
result
entri
assay
addit
nitazoxanid
present
minor
inhibit
postinfect
stage
post
impli
inhibit
nitazoxanid
chikv
genom
synthesi
besid
product
chikv
progeni
determin
use
tcid
assay
fig
analyz
releas
chikv
virion
compound
abl
suppress
product
chikv
progeni
postinfect
stage
post
indic
inhibit
viru
releas
besid
niclosamid
show
abil
inhibit
progeni
product
infect
stage
co
meant
niclosamid
possess
high
efficaci
viru
entri
even
though
niclosamid
treat
infect
still
affect
viru
progeni
product
celltocel
transmiss
anoth
import
pathway
chikv
transmiss
hahon
zimmerman
previou
find
suramin
possess
antichikv
abil
cell
fusion
also
transmiss
ie
releas
celltocel
transmiss
ho
et
al
result
show
niclosamid
nitazoxanid
abl
inhibit
chikv
entri
disrupt
releas
chikv
virion
therefor
analyz
role
niclosamid
nitazoxanid
play
celltocel
transmiss
cell
infect
chikv
moi
h
incub
medium
replac
fresh
medium
contain
chikv
neutral
antibodi
indic
drug
chikv
neutral
antibodi
ad
neutral
releas
chikv
progeni
therefor
area
chikv
infect
consid
caus
celltocel
transmiss
infect
area
determin
dsrna
stain
shown
fig
niclosamid
nitazoxanid
significantli
reduc
area
chikv
infect
result
also
indic
niclosamid
nitazoxanid
significantli
reduc
celltocel
transmiss
dosedepend
manner
fig
determin
antivir
spectrum
niclosamid
nitazoxanid
cell
infect
two
differ
clinic
strain
chikv
ie
mutant
strain
well
two
alphavirus
sinv
sfv
moi
cell
treat
variou
dosag
niclosamid
nitazoxanid
h
incub
cell
lysat
use
extract
intracellular
rna
analyz
rtqpcr
defin
ec
niclosamid
ec
valu
mm
differ
chikv
strain
ec
valu
sinv
sfv
mm
respect
select
index
ec
determin
use
rtqpcr
present
mean
sd
n
b
cc
determin
use
assay
present
mean
sd
n
c
si
select
index
repres
ratio
cc
ec
cell
kind
human
bone
osteosarcoma
epitheli
cell
abl
infect
chikv
niclosamid
nitazoxanid
show
inhibit
chikv
infect
chikv
ec
niclosamid
nitazoxanid
cc
si
taken
togeth
evid
indic
niclosamid
nitazoxanid
possess
potenti
becom
antichikv
drug
chikv
classifi
risk
pathogen
howev
baculovirusbas
express
system
safe
oper
laboratori
therefor
use
chikv
mediat
insect
cell
fusion
inhibit
assay
decreas
risk
ht
search
antichikv
drug
studi
four
fda
approv
drug
show
abil
block
cell
fusion
howev
two
niclosamid
nitazoxanid
confirm
antichikv
effect
fig
fig
entri
assay
use
verifi
inhibit
mechan
drug
earli
infect
niclosamid
nitazoxanid
show
inhibit
abil
earli
stage
chikv
infect
fig
furthermor
drug
abl
inhibit
two
chikv
clinic
isol
also
two
alphavirus
well
tabl
experiment
data
indic
compound
possess
broad
antialphaviru
abil
antichikv
activ
niclosamid
nitazoxanid
also
prove
use
cell
verifi
potenti
use
human
cell
tabl
previou
studi
indic
niclosamid
proton
carrier
target
acid
endosom
broad
antivir
effect
jurgeit
et
al
nitazoxanid
also
consid
broadspectrum
antivir
agent
use
treat
dengu
yellow
fever
jev
respiratori
syncyti
viru
rsv
parainfluenza
coronaviru
rotaviru
noroviru
hepat
b
hbv
hepat
c
hcv
human
immunodefici
viru
hiv
rossignol
furthermor
nitazoxanid
found
inhibit
earli
midstag
japanes
enceph
viru
jev
infect
shi
et
al
base
find
suggest
niclosamid
nitazoxanid
might
possess
broad
antialphaviru
abil
suppress
earli
stage
chikv
infect
timeofaddit
assay
cell
lysat
supernat
separ
analyz
rtqpcr
tcid
assay
depend
assay
design
intracellular
chikv
rna
use
determin
effect
test
compound
viru
bind
preinfect
pre
viru
entri
infect
co
viral
genom
replic
postinfect
post
moreov
tcid
assay
conduct
postinfect
stage
use
quantifi
extracellular
chikv
progeni
ie
viral
releas
niclosamid
treatment
infect
co
significantli
reduc
intracellular
chikv
rna
level
fig
moreov
product
extracellular
chikv
progeni
significantli
reduc
cell
treat
niclosamid
postinfect
stage
fig
result
impli
niclosamid
could
affect
viru
entri
releas
nitazoxanid
also
decreas
intracellular
chikv
rna
level
ad
infect
co
postinfect
post
fig
besid
nitazoxanid
abl
suppress
product
chikv
progeni
postinfect
stage
fig
previou
studi
indic
nitazoxanid
antivir
activ
post
infect
influenza
viru
rotaviru
rossignol
nitazoxanid
might
affect
influenza
viru
assembl
rossignol
et
al
rotaviru
replic
la
frazia
et
al
data
also
suggest
nitazoxanid
might
possess
inhibit
abil
viru
entri
genom
synthesi
viru
releas
viru
transmiss
includ
extracellular
transmiss
viru
releas
intracellular
transmiss
celltocel
transmiss
celltocel
transmiss
consid
import
transmiss
pathway
allow
virus
avoid
attack
immun
system
previou
studi
indic
chikv
structur
protein
might
involv
viru
bind
fusion
also
viru
releas
masrinoul
et
al
celltocel
transmiss
lee
et
al
previou
studi
indic
suramin
abl
inhibit
viru
entri
fusion
releas
celltocel
transmiss
ho
et
al
data
prove
niclosamid
nitazoxanid
abl
inhibit
viru
entri
releas
furthermor
niclosamid
nitazoxanid
test
found
significantli
suppress
celltocel
transmiss
chikv
infect
studi
first
demonstr
two
compound
inhibit
celltocel
transmiss
chikv
infect
conclus
chikv
mediat
insect
cell
fusion
assay
could
use
search
antichikv
drug
use
platform
found
determin
niclosamid
nitazoxanid
possess
antichikv
abil
investig
two
compound
affect
chikv
entri
transmiss
also
possess
broad
antialphavirus
abil
niclosamid
nitazoxanid
could
use
develop
antichikv
antialphaviru
drug
futur
formul
alter
combin
antichikv
drug
abl
improv
drug
efficaci
reduc
dosag
besid
structur
modif
find
novel
deriv
also
anoth
way
develop
safe
efficaci
antichikv
drug
